CBER User Fee Standards May Need To Differ From CDER's, Director Zoon Says

The Center for Biologics Evaluation & Research may need a different set of user fee review parameters than the drug center, CBER Director Kathryn Zoon, PhD, suggested during a Dec. 7 FDA public meeting on the Prescription Drug User Fee Act